Market Overview

UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns

Related ARNA
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine

JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA) with a Neutral rating and lowered the price target from $8.00 to $7.00.

JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia (including slow uptake and a meaningful number of pts not filling their prescription due to a relatively high out-of-pocket cost). In fact, Belviq could well experience a more lackluster launch vs. Qsymia given the drug's higher price and more modest level of efficacy. Maintain Neutral."

Arena Pharmaceuticals closed at $8.34 on Monday.

Latest Ratings for ARNA

DateFirmActionFromTo
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

Around the Web, We're Loving...

Get Benzinga's Newsletters